A director at Visa Inc sold 909 shares at 275.547USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma $15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger® Technology to Optimize CAR T Cell Expansion and Persistence SOUTH SAN FRANCISCO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology comp...
A director at Kimberly Clark Corp sold 1,465 shares at 136.910USD and the significance rating of the trade was 48/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Crown Castle Highlights Actions its Board Has Implemented to Successfully Strengthen Foundation and Position Company for Long-Term Value Creation Urges Shareholders to Vote “FOR” ONLY Crown Castle’s 12 Qualified and Experienced Director Nominees on the WHITE Proxy Card Ted Miller’s Self-Serving Campaign Risks Derailing Important Work Underway and Is Not Aligned with Interests of Shareholders HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today sent a letter to shareholders in connection with its upcoming 2024 Annual Meeting of...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Vital Farms to Report First Quarter 2024 Financial Results on May 9, 2024 AUSTIN, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, will report financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, before market open. Vital Farms will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. To participate on the call and receive dial in information, please register here: The live conference call webcast can also be...
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and...
Northrop Grumman Releases First Quarter 2024 Financial Results FALLS CHURCH, Va., April 25, 2024 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) has released its first quarter 2024 financial results. A copy of the earnings release has been furnished in the company’s Form 8-K filing and is also available on the company's investor relations website at . As previously announced, Northrop Grumman will webcast its earnings conference call at 9 a.m. Eastern time today. A live audio broadcast of the conference call will be available on . To listen to the call, go to the website a...
Four Directors at Kroger Co sold after exercising options/sold 131,705 shares at between 55.520USD and 57.180USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo® (cemiplimab-rwlc) 17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Reg...
Shifting Exposure From Growth to Value Note: This is an abbreviated report (no detailed Sector comments or Russell grids). We will return to our normal report structure next week. While the market remains in consolidation/pullback mode and we are not out of the woods, it is possible that further downside is limited from here on the S&P 500. Since late-February, we have discussed important gap support from 2/22/24 at 4983-5050 on the S&P 500, and that as long as the S&P 500 is above 4983 that b...
Heartland Express, Inc. Reports Operating Results for the First Quarter of 2024 NORTH LIBERTY, Iowa, April 23, 2024 (GLOBE NEWSWIRE) -- Heartland Express, Inc. (Nasdaq: HTLD) announced today financial results for the three months ended March 31, 2024. Three months ended March 31, 2024: Operating Revenue of $270.3 million,Net Loss of $15.1 million, Basic Loss per Share of $0.19,Operating Ratio of 105.3% and 105.6% Non-GAAP Adjusted Operating Ratio(1),Total Assets of $1.5 billion,Stockholders' Equity of $848.8 million. Heartland Express Chief Executive Officer Mike Gerdin com...
SFL - Acquisition of two LNG dual-fuel chemical carriers in combination with long term employment SFL Corporation Ltd. (NYSE: SFL) (“SFL” or the “Company”) today announced that it has agreed to acquire two LNG dual-fuel 33,000 dwt chemical carriers. The vessels are built in 2022/2023 and fitted with stainless steel cargo tanks, and the aggregate purchase price is approximately $114 million. SFL has arranged long term employment for the vessels with affiliates of Stolt Tankers, a subsidiary of the world-leading chemical logistics company Stolt-Nielsen Limited (“Stolt-Nielsen”). The Co...
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be pres...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.